Some of the most common safety risks for patients receiving dialysis include medication safety, infections, and falls, according to Alan Kliger, MD, clinical professor of medicine at Yale University School of Medicine.
Some of the most common safety risks for patients receiving dialysis include medication safety, infections, and falls, according to Alan Kliger, MD, clinical professor of medicine at Yale University School of Medicine.
Transcript
What are the major safety risks of dialysis, and how common are they?
Patients on dialysis are complex; they have multisystem disease and therefore the possibility of problems, the possibility of errors, the possibility of safety issues is higher than for other patients. Patients on dialysis have particular areas of safety concern. First is medications; patients on dialysis often take more than 6 and sometimes more than 16 different medications, each with different time intervals, each with different indications, sometimes with interactions, and so medication safety, taking the right medicine at the right time in the right combinations, is a major safety issue for patients.
A second is infections, something that I’ve been involved with recently. Eleven percent of dialysis patients die as a direct result of infections, making it the second leading cause of death only after heart and vascular disease. And more hospital days are spent as a result of infection than cardiovascular disease. So infection and particularly preventable infections is a substantial source of safety problems for patients.
Other things include falls, which are common and often incapacitating when they result in fracture for patients on dialysis. And vascular access issues, issues around the fistula, bleeding catheter problems. So those are sort of the major risks of dialysis patients.
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More